(Flash player required for above)

September 8-11, 2007
Providence, Rhode Island, USA

The annual meeting environment encompassed various in vivo and in vitro imaging methods, including discussion of optical imaging, ultrasound, CT, PET, SPECT, MRI, multi-modality imaging, new molecular imaging agents and probes and the application of imaging to drug development. Thank you to those who joined us to explore the present and future status of cellular and molecular studies in the context of the whole organism.

Program Co-Chairmen
Thomas Budinger (Co-Chair), University of California Berkeley, Berkeley, USA
Sanjiv (Sam) Gambhir (Co-Chair), Stanford University, Stanford, USA

Steering Committee
James Basilion, Case Western Reserve University, Cleveland, USA
Thomas Budinger (Co-Chair), University of California Berkeley, Berkeley, USA
Simon Cherry, University of California, Davis, Davis, USA
Johannes Czernin, University of California, Los Angeles, Los Angeles, USA
Marcelo Di Carli, Brigham and Women’s Hospital, Boston, USA
Joseph Frank, National Institutes of Health, Bethesda, USA
Sanjiv (Sam) Gambhir (Co-Chair), Stanford University, Stanford, USA
Robert Gillies, University of Arizona, Tucson, USA
Robert Lenkinski, Beth Israel Deaconess Medical Center, Boston, USA
Timothy McCarthy, Pfizer Global R&D, Groton, USA
Thomas Meade, Northwestern University, Evanston, USA
David Piwnica-Worms, Washington Univ. Molecular Imaging Ctr., St. Louis, USA
Brian Ross, University of Michigan, Ann Arbor, USA
Markus Schwaiger, Technische Universität München, München, Germany
Bertrand Tavitian, CEA, Orsay, France
Wolfgang Weber, University of California, Los Angeles, Los Angeles, USA
Ralph Weissleder, Massachusetts General Hospital, Harvard, Boston, USA

Pre-Conference Symposium
The 2007 meeting featured a Pre-Conference Symposium on Clinical Molecular Imaging and was jointly sponsored by the RSNA, AMI, SMI and SNM. The Pre-Conference Symposium provided an introduction and overview of molecular imaging to radiologists, nuclear medicine physicians, oncologists, cardiologists and other physicians and trainees with a clinical interest in molecular imaging. Additionally, two distinct tracks within the Pre-Conference Symposium focused on clinical PET and PET/CT imaging for physicians, technologists and administrators.

Who Attended?
The audience of the JMIC consisted of researchers, clinical practitioners, trainees and other professionals in radiology, neuroradiology, neuroscience, oncology, nuclear medicine, cardiology, medical physics, cell biology, molecular biology, genetics, immunology and medical imaging equipment companies.

Educational Objectives:

• Explain methods of target identification and probe development for disease targets.
• Describe effective approaches to cancer and cardiac disease detection and outcome measures.
• Describe current state-of-the-art detection and outcome measures of neurodegenerative disorders.
• Compare data from various molecular imaging modalities that demonstrate significant advantages of different imaging strategies.
• Evaluate the potential of new imaging methods to detect disease early in its course and recognize when there is the potential for improved outcome.
• Describe the new imaging paradigms in drug discovery and development.
• Recommend imaging and therapy combinations.
• Appraise the role of molecular imaging in cellular, stem cell, and gene therapies.
  
  
  

The Society for Molecular Imaging
Charles Metzger, Executive Director
PO Box 293878, Kerrville, TX 78029-3878 USA
1-830-257-0112; Fax: 1-830-257-0119
Email: cmetzger@molecularimaging.org

Academy of Molecular Imaging
Box 951735, Los Angeles, CA 90095-1735 USA
Tel. 1-310-267-2614 Fax: 1-310 267-2617
Email: ami@mednet.ucla.edu